Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study

著录项

• 来源
  《Clinical and experimental rheumatology》 |2016年第100期|共7页
• 作者

  Owen C.; Ngian G-S.; Elford K.; Moore O.; Stevens W.; Nikpour M.; Rabusa C.; Proudman S.; Roddy J.; Zochling J.; Hill C.; Sturgess A.; Tymms K.; Youssef P.; Sahhar J.;

  展开▼
• 作者单位

  Monash Hlth Dept Rheumatol Clayton Vic Australia;

  Monash Hlth Dept Rheumatol Clayton Vic Australia;

  Monash Hlth Dept Rheumatol Clayton Vic Australia;

  Derriford Hosp Plymouth Devon England;

  St Vincents Hosp Melbourne Vic Australia;

  St Vincents Hosp Melbourne Vic Australia;

  St Vincents Hosp Melbourne Vic Australia;

  Royal Adelaide Hosp Adelaide SA Australia;

  Royal Perth Hosp Perth WA Australia;

  Menzies Inst Med Res Hobart Tas Australia;

  Queen Elizabeth Hosp Woodville SA Australia;

  St George Hosp Kogarah NSW Australia;

  Canberra Hosp Garran ACT Australia;

  Royal Prince Alfred Hosp Camperdown NSW Australia;

  Monash Hlth Dept Rheumatol Clayton Vic Australia;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 免疫性疾病;
• 关键词

  systemic sclerosis; interstitial lung disease; mycophenolate mofetil; azathioprine;

  机译：全身硬化;间质肺病;霉酚酸酯;AzathioPrine;